BioSpace News Archive

Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance, today reports financial results for the three and six months ended June 30, 2018.

Electromed, Inc. (NYSE American:ELMD) today announced the results of an independent, outcome-based clinical study presented during the third annual World Bronchiectasis Conference in Washington D.C.